Human epidermal growth factor receptor 2 (HER2), which determines histopathological molecular subtypes along with estrogen receptor (ER) and progesterone receptor (PR), is an important indicator for the treatment and prognosis of breast cancer. This evidence concerns the gene PGR and breast carcinoma.